Chief Scientific Officer Andrew King Sells 1,168 Shares of Chinook Therapeutics Inc
| KDNYDelisted Stock | USD 39.25 0.20 0.51% |
Slightly above 53% of Chinook Therapeutics' investor base is interested to short. The analysis of current outlook of investing in Chinook Therapeutics suggests that many traders are impartial regarding Chinook Therapeutics' prospects. Chinook Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Chinook Therapeutics' earnings reports, geopolitical events, and overall market trends.
Chinook |
GuruFocus Article or News written by GuruFocus Research and the topic is about
Read at gurufocus.com
 |
Chinook Therapeutics Fundamental Analysis
We analyze Chinook Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chinook Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chinook Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Chinook Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Chinook Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Chinook Therapeutics stock to make a market-neutral strategy. Peer analysis of Chinook Therapeutics could also be used in its relative valuation, which is a method of valuing Chinook Therapeutics by comparing valuation metrics with similar companies.
Peers
Chinook Therapeutics Related Equities
| PLRX | Pliant Therapeutics | 2.00 | ||||
| DAWN | Day One | 1.53 | ||||
| VTYX | Ventyx Biosciences | 1.13 | ||||
| TVTX | Travere Therapeutics | 0.59 | ||||
| PCVX | Vaxcyte | 0.38 | ||||
| NUVL | Nuvalent | 0.08 | ||||
| ASND | Ascendis Pharma | 0.18 | ||||
| KALV | Kalvista Pharmaceuticals | 0.30 | ||||
| SWTX | SpringWorks Therapeutics | 0.60 | ||||
| RNA | Avidity Biosciences | 0.69 | ||||
| CRNX | Crinetics Pharmaceuticals | 0.81 | ||||
| ACLX | Arcellx | 1.12 | ||||
| KURA | Kura Oncology | 1.16 | ||||
| RVMD | Revolution Medicines | 1.25 | ||||
| VRDN | Viridian Therapeutics | 1.46 | ||||
| GPCR | Structure Therapeutics | 1.78 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Chinook Stock
If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |